PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia

Leukemia Research

Volumn 31, Issue 7, 2007, Pages 891-897

  Giles, Francis J ^a   List, Alan F ^b   Carroll, Michael ^b   Cortes, Jorge E ^a   Valickas, Joyce ^c   Chen, Bee Lian ^c   Masson, Eric ^c   Jacques, Christian ^c   Laurent, Dirk ^d   Albitar, Maher ^a   Feldman, Eric J ^e   Roboz, Gail J ^e  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d BAYER PHARMA AG   (Germany)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Angiogenesis; Myelofibrosis; Tyrosine kinase inhibitor; VEGF

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN; VATALANIB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; HUMAN; HYPOKALEMIA; LIVER FUNCTION TEST; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELOFIBROSIS; MYELOID METAPLASIA; NAUSEA; NEPHROLITHIASIS; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; REMISSION; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; PHTHALAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; TISSUE DISTRIBUTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34249826968     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.12.001     Document Type: Article

References (41)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 (1995) 27-31
2. Aguayo A., Giles F., and Albitar M. Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. Leuk Lymphoma 44 (2003) 213-222
3. Giles F.J. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies. Oncologist 6 Suppl. 5 (2001) 32-39
4. Dvorak H.F., Detmar M., Claffey K.P., et al. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 107 (1995) 233-235
5. Glade-Bender J., Kandel J.J., and Yamashiro D.J. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 3 (2003) 263-276
6. Mesa R.A., Hanson C.A., Rajkumar S.V., et al. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 96 (2000) 3374-3380
7. Arora B., Ho C.L., Hoyer J.D., et al. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia. Haematologica 89 (2004) 1454-1458
8. Ni H., Barosi G., and Hoffman R. Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis. Am J Clin Pathol 126 (2006) 241-247
9. Ho C.L., Arora B., Hoyer J.D., et al. Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia. Eur J Haematol 74 (2005) 35-39
10. Musolino C., Calabro L., Bellomo G., et al. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol 69 (2002) 159-163
11. Wood J.M., Bold G., Buchdunger E., et al. PTK787/ZK, 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60 (2000) 2178-2189
12. Drevs J., Hofmann I., Hugenschmidt H., et al. Effects of PTK787/ZK, 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60 (2000) 4819-4824
13. Hess C., Vuong V., Hegyi I., et al. Effect of VEGF receptor inhibitor PTK787/ZK 222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 85 (2001) 2010-2016
14. Drevs J., Muller-Driver R., Wittig C., et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62 (2002) 4015-4022
15. Schoenberger J., Grimm D., Kossmehl P., et al. Effects of PTK787/ZK 222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology 145 (2004) 1031-1038
16. Klem J. Current studies with PTK787/ZK 222584, an oral inhibitor of vascular endothelial growth factor in colorectal cancer. Clin Colorectal Cancer 3 (2003) 147-149
17. Goldbrunner R.H., Bendszus M., Wood J., et al. PTK787/ZK 222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 55 (2004) 426-432 [discussion 32]
18. Drevs J., Zirrgiebel U., Schmidt-Gersbach C.I., et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16 (2005) 558-565
19. Thomas A.L., Morgan B., Horsfield M.A., et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23 (2005) 4162-4171
20. Rudin M., McSheehy P.M., Allegrini P.R., et al. PTK787/ZK 222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo. NMR Biomed 18 (2005) 308-321
21. Tyagi P. Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin Colorectal Cancer 5 (2005) 24-26
22. Roboz G.J., Giles F.J., List A.F., et al. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 20 (2006) 952-957
23. Jost L, Gschwind HP, Jalava T, et al., Metabolism and disposition of vatalanib (Ptk787/Zk 222584) in cancer patients. Drug Metab Dispos 2006.
24. Tefferi A., Barosi G., Mesa R.A., et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for myelofibrosis research and treatment (IWG-MRT). Blood 108 (2006) 1497-1503
25. Morgan B., Thomas A.L., Drevs J., et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21 (2003) 3955-3964
26. Di Raimondo F., Palumbo G.A., Molica S., et al. Angiogenesis in chronic myeloproliferative diseases. Acta Haematol 106 (2001) 177-183
27. Giles F.J., Cooper M.A., Silverman L., et al. Phase II study of SU5416-a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor-in patients with refractory myeloproliferative diseases. Cancer 97 (2003) 1920-1928
28. Zangari M., Anaissie E., Stopeck A., et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 10 (2004) 88-95
29. Giles F.J., Stopeck A.T., Silverman L.R., et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 102 (2003) 795-801
30. Pozzato G., Zorat F., Nascimben F., et al. Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia. Haematologica 86 (2001) 772-773
31. Barosi G., Grossi A., Comotti B., et al. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 114 (2001) 78-83
32. Canepa L., Ballerini F., Varaldo R., et al. Thalidomide in agnogenic and secondary myelofibrosis. Br J Haematol 115 (2001) 313-315
33. Elliott M.A., Mesa R.A., Li C.Y., et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 117 (2002) 288-296
34. Merup M., Kutti J., Birgergard G., et al. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med Oncol 19 (2002) 79-86
35. Piccaluga P.P., Visani G., Pileri S.A., et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia 16 (2002) 1609-1614
36. Giovanni B., Michelle E., Letizia C., et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma 43 (2002) 2301-2307
37. Thomas D.A., Giles F.J., Albitar M., et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 106 (2006) 1974-1984
38. Mesa R.A., Elliott M.A., Schroeder G., et al. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc 79 (2004) 883-889
39. Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol 32 (2005) S24-S30
40. Tefferi A., Cortes J., Verstovsek S., et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108 (2006) 1158-1164
41. Giles F.J., Bellamy W.T., Estrov Z., et al. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res 30 (2006) 801-811